Long Term Debt Summary of Azitra, Inc.

Azitra, Inc.'s latest annual long term debt in 2023 was 563.69 Thousand USD , down -92.42% from previous year.
Azitra, Inc.'s latest quarterly long term debt in 2024 Q2 was 414.31 Thousand USD , down 0.0% from previous quarter.
Azitra, Inc. reported annual long term debt of 7.44 Million USD in 2022, up 650.08% from previous year.
Azitra, Inc. reported annual long term debt of 992.01 Thousand USD in 2021, down 0.0% from previous year.
Azitra, Inc. reported quarterly long term debt of 478.61 Thousand USD for 2024 Q1, down 0.0% from previous quarter.
Azitra, Inc. reported quarterly long term debt of 643.52 Thousand USD for 2023 Q3, down -7.22% from previous quarter.

Annual Long Term Debt Chart of Azitra, Inc. (2023 - 2021)

Name	Long Term Debt	Long Term Debt Difference
AIM ImmunoTech Inc.	495 Thousand USD	-13.877%
Ampio Pharmaceuticals, Inc.	- USD	-Infinity%
Armata Pharmaceuticals, Inc.	82.3 Million USD	99.315%
Actinium Pharmaceuticals, Inc.	1.57 Million USD	64.142%
Can-Fite BioPharma Ltd.	13 Thousand USD	-4236.092%
Chromocell Therapeutics Corporation	- USD	-Infinity%
Calidi Biotherapeutics, Inc.	2.06 Million USD	72.636%
CEL-SCI Corporation	11.6 Million USD	95.142%
iBio, Inc.	3.5 Million USD	83.927%
Lineage Cell Therapeutics, Inc.	2.07 Million USD	72.769%
MAIA Biotechnology, Inc.	- USD	-Infinity%
Matinas BioPharma Holdings, Inc.	2.89 Million USD	80.529%
Navidea Biopharmaceuticals, Inc.	1.87 Million USD	69.884%
NovaBay Pharmaceuticals, Inc.	1.1 Million USD	49.125%
NanoViricides, Inc.	- USD	-Infinity%
Oragenics, Inc.	- USD	-Infinity%
BiomX Inc.	5.4 Million USD	89.565%
BiomX Inc.	5.4 Million USD	89.565%
Protalix BioTherapeutics, Inc.	4.62 Million USD	87.802%
Palatin Technologies, Inc.	163.78 Thousand USD	-244.172%
Scorpius Holdings, Inc.	12.61 Million USD	95.531%
Theriva Biologics, Inc.	162 Thousand USD	-247.958%